Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Parallel, Randomized, Multi-center Study to Evaluate the Safety and Immunogenicity of Different Formulations of Multivalent Influenza and Respiratory Syncytial Virus (RSV)/Human Metapneumovirus (hMPV)/Parainfluenza Virus Type 3 (PIV3) Vaccines in Healthy Participants 18 to 49 Years of Age.

NCT06850051 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT06850051
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06850051 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Parallel, Randomized, Multi-center Study to Evaluate the Safety and Immunogenicity of Different Formulations of Multivalent Influenza and Respiratory Syncytial Virus (RSV)/Human Metapneumovirus (hMPV)/Parainfluenza Virus Type 3 (PIV3) Vaccines in Healthy Participants 18 to 49 Years of Age.
Lead sponsor
Sanofi
Phase
Phase 1
Overall status
Completed
Start date
March 19, 2025
Completion date
December 11, 2025
Enrollment
270 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers, human metapneumovirus vaccination, influenza vaccination, parainfluenza vaccination, respiratory syncytial virus vaccination